Drug Combination Details
| General Information of the Combination (ID: C18543) | |||||
|---|---|---|---|---|---|
| Name | Gambogic acid NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Osteosarcoma
[ICD-11: 2B51]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ERK2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| In-vivo Model | To determine the in vivo antitumour activity of GA combined with CDDP, viable A549 cells (5 * 106/100ul PBS per mouse) were subcutaneously injected into the right flank of 7- to 8-week-old male SCID mice. | |||||
| Experimental
Result(s) |
Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-KappaB and MAPK/HO-1 signalling. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | LRP/LR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SYCE1L | Molecule Info | |||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. | |||||
| Experiment 3 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MG-63 | CVCL_0426 | Osteosarcoma | Homo sapiens | ||
| HOS | CVCL_0312 | Osteosarcoma | Homo sapiens | |||
| U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
GA could increase the chemotherapeutic effect of CDDP in human osteosarcoma treatment through inducing the cell cycle arrest and promoting cell apoptosis. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCC1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MG-63 | CVCL_0426 | Osteosarcoma | Homo sapiens | ||
| HOS | CVCL_0312 | Osteosarcoma | Homo sapiens | |||
| In-vivo Model | 0.2 mL of MG63 cell suspension (1.5*107 cells/ml) was subcutaneously injected into the right flank of mice. | |||||
| Experimental
Result(s) |
Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1Alpha. | |||||
